|
Dental Plaque
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We performed regression analyses for levels of 3 periodontopathogens in subgingival dental plaques (Porphyromonas gingivalis [Pg], Treponema denticola [Td], and Tannerella forsythia [Tf]) and 3 clinical measures of PD (periodontal probing depth [PPD], gingival recession [REC], and bleeding on probing [BOP]).
|
27727278 |
2016 |
|
Depression, Postpartum
|
0.010 |
Biomarker
|
disease |
BEFREE |
International studies suggest that PPD is characterized by additional symptoms compared to maternal postpartum depression.
|
31533685 |
2019 |
|
Depressive Symptoms
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
We estimate linear models of the effect of drug-related violence (CIDE-PPD database) on depression symptoms (MxFLS 2009-2012).
|
30114594 |
2018 |
|
Depressive Symptoms
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
<b>Discussion:</b> Be a Mom promotes the enhancement of women's emotion regulation abilities and self-compassion, and this seems to exert a protective effect in the presence of PPD risk factors (or early-onset symptoms) because it led to a reduction of depressive symptoms.
|
30873060 |
2019 |
|
Diagnosis, Psychiatric
|
0.010 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to replicate the predictive efficacy of the previously established model in women with and without a previous psychiatric diagnosis and to understand the effects of changing hormone levels on PPD biomarker loci.
|
26503311 |
2016 |
|
Dopa-Responsive Dystonia
|
0.080 |
Biomarker
|
disease |
BEFREE |
These results suggest that some novel mutations should exist on one of the alleles in some unknown region of the GCH1 gene, and may decrease the GCH1 mRNA causing the HPD/DRD symptoms.
|
10403837 |
1999 |
|
Dopa-Responsive Dystonia
|
0.080 |
Biomarker
|
disease |
BEFREE |
In juvenile parkinsonism and Parkinson's disease, which have dopamine deficiency in the basal ganglia as HPD/DRD, the GCH gene may be normal, and the molecular mechanism of the dopamine deficiency in the basal ganglia is different from that in HPD/DRD.
|
10079965 |
1999 |
|
Dopa-Responsive Dystonia
|
0.080 |
Biomarker
|
disease |
BEFREE |
Hereditary progressive dystonia with marked diurnal fluctuation/dopa-responsive dystonia (HPD/DRD) shows the considerable heterogeneity of clinical phenotypic expression and a dramatic sustained response to levodopa.
|
15165667 |
2004 |
|
Dopa-Responsive Dystonia
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
We found that mutations of GTP cyclohydrolase I, the rate-limiting enzyme in the biosynthesis of tetrahydrobiopterin, which is the cofactor of dopamine-synthesizing tyrosine hydroxylase, cause dominantly inherited hereditary progressive dystonia with marked diurnal fluctuation (HPD, Segawa's disease) probably owing to the decrease of dopamine in the basal ganglia.
|
9205791 |
1997 |
|
Dopa-Responsive Dystonia
|
0.080 |
Biomarker
|
disease |
BEFREE |
The causative gene for hereditary progressive dystonia with marked diurnal fluctuation/dopa-responsive dystonia (HPD/DRD) was discovered in 1994 to be guanosine triphosphate (GTP) cyclohydrolase I, an enzyme involved in tetrahydrobiopterin biosynthesis.
|
10984669 |
2000 |
|
Dopa-Responsive Dystonia
|
0.080 |
Biomarker
|
disease |
BEFREE |
Kinetics of catecholamine biosynthesis and metabolism have been examined in patients with hereditary progressive dystonia with marked diurnal fluctuation of symptoms (HPD, Segawa's disease).
|
2716962 |
1989 |
|
Dopa-Responsive Dystonia
|
0.080 |
Biomarker
|
disease |
BEFREE |
Previous clinical investigations of HPD/DRD have shown a predominance of affected women, with approximately half of HPD/DRD patients being sporadic.
|
9566388 |
1998 |
|
Dopa-Responsive Dystonia
|
0.080 |
Biomarker
|
disease |
BEFREE |
We characterized the GTP cyclohydrolase I (GTP-CH-I) gene in a patient with hereditary progressive dystonia with marked diurnal fluctuation/dopa-responsive dystonia (HPD/DRD).
|
9177267 |
1997 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy.
|
16099942 |
2005 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
A performance evaluation of three drug-induced liver injury biomarkers in the rat: alpha-glutathione S-transferase, arginase 1, and 4-hydroxyphenyl-pyruvate dioxygenase.
|
22872058 |
2012 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Taken together, these novel liver toxicity biomarkers, GSTA, ARG1, and HPD, add value (both enhanced specificity and sensitivity) to the measurement of ALT alone for monitoring drug-induced liver injury in rat.
|
22872058 |
2012 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy.
|
16099942 |
2005 |
|
Dystonia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Mutations of GCH result in reductions in GCH activity, BH4, TH activity, and dopamine, causing either recessively inherited GCH deficiency or dominantly inherited hereditary progressive dystonia [HPD; Segawa's disease; also called dopa-responsive dystonia (DRD)].4.
|
10079965 |
1999 |
|
Dystonia Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Mutations of GCH result in reductions in GCH activity, BH4, TH activity, and dopamine, causing either recessively inherited GCH deficiency or dominantly inherited hereditary progressive dystonia [HPD; Segawa's disease; also called dopa-responsive dystonia (DRD)].4.
|
10079965 |
1999 |
|
Enzyme inhibition disorder
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Metabolome patterns indicative for liver effects and 4-hydroxyphenylpyruvate dioxygenase (HPPD) enzyme-inhibition were established in pregnant rats based on regulated metabolites using reference compounds.
|
30414988 |
2019 |
|
Failure to Thrive
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Familial (FPAH)
|
0.010 |
Biomarker
|
disease |
BEFREE |
There is substantial but less consistent evidence for a familial relationship between PPD and SCZ: three of six studies supported such a relationship, but one large study reported increased familial risk of PPD for AD and not for SCZ probands.
|
8297808 |
1993 |
|
FG syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, eight of 12 patients with FGS who had the M1 (Ala213) V or S alleles but were PPD negative did not require transplantation.
|
9475086 |
1998 |
|
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ginsenoside 25-OCH<sub>3</sub>-PPD Promotes Activity of LXRs To Ameliorate P2X7R-Mediated NLRP3 Inflammasome in the Development of Hepatic Fibrosis.
|
29929367 |
2018 |
|
Fine hair
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|